Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 18/20 | 0.58 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7285302 | 0.86 | ERN1 (0.62) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL28292328 | 0.81 | ERN1 (0.61) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL3645435 | 0.81 | ERN1 (0.61) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL28282933 | 0.81 | ERN1 (0.56) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL29025470 | 0.80 | CYP3A4 (0.50) | ALDH1A1 | |
| SCHEMBL118908 | 0.79 | ERN1 (0.68) | ERN1ALDH1A1 | |
| SCHEMBL13855640 | 0.79 | ERN1 (0.55) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL931983 | 0.79 | ERN1 (0.60) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL3928147 | 0.78 | ERN1 (0.58) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL13980464 | 0.78 | ERN1 (0.53) | ERN1TRIM24TYRTRIM33ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3368544-B1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3368544-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | H. Hoffnabb-La Roche Ag (CH) | 2018-09-05 | — | — | EP | disclosed |
| CN-108350028-A | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | 豪夫迈·罗氏有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180022716-A1 | POLYMERIZABLE COMPOUND AND OPTICAL ISOMER | DIC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| WO-2017147047-A1 | FXR MODULATORS AND METHODS OF THEIR USE | ALIOS BIOPHARMA, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-1149069-B1 | PHENYLGLYCINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2004-02-19 | — | — | US | disclosed |
| US-6683215-B2 | TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION AND ARTERIOSCLEROSIS, WHICH ARE ASSOCIATED WITH COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA AND TISSUE FACTOR; ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2003-05-01 | — | — | US | disclosed |
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | ERN1 2560/4885TRIM24 1373/4885TYR 2485/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | ERN1 2560/4885TRIM24 1373/4885TYR 2485/4885 |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ERN1 1281/4885TRIM24 4073/4885TYR 4365/4885 |
| US-20180022716-A1 | POLYMERIZABLE COMPOUND AND OPTICAL ISOMER | SMC4, MAP1LC3C, ZW10 | ERN1 2084/4885TRIM24 1527/4885TYR 55/4885 |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | ERN1 2560/4885TRIM24 1373/4885TYR 2485/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ERN1 1281/4885TRIM24 4073/4885TYR 4365/4885 |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ERN1 1281/4885TRIM24 4073/4885TYR 4365/4885 |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | VIP, ARG1, CX3CR1 | ERN1 2560/4885TRIM24 1373/4885TYR 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.